JCR Pharmaceuticals Co., Ltd.

4552

JP3701000006

Pharmaceuticals

Delayed Japan Exchange Other stock markets 07:00:00 26/06/2024 BST			5-day change	1st Jan Change
606 ^JPY	0.00%		+3.95%	-48.29%

06-24	JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from S&P Japan 500	CI
05-31	JCR Pharmaceuticals' Full-Year Profit Up 46%	MT

Jcr Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Period Second Quarter and Full Year of Year Ending March 31, 2025

May 10, 2024 at 08:00 am

JCR Pharmaceuticals Co., Ltd. provides dividend guidance of JPY 10 per share for the period Second quarter for year ending March 31, 2025.

The company provided dividend guidance of JPY 10 per share for the period of full year ending March 31, 2025.

Latest news about JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from S&P Japan 500	06-23	CI
JCR Pharmaceuticals' Full-Year Profit Up 46%	05-31	MT
Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold	05-27	MT
Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	05-10	CI
Jcr Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Period Second Quarter and Full Year of Year Ending March 31, 2025	05-10	CI
JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024	05-10	CI
JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024	04-25	CI
US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	03-21	MT
JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	03-21	MT
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	03-19	CI
JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index	03-17	CI
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd	03-12	CI
JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes	02-28	CI
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier	02-14	CI
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-09	CI
Asia Markets Remain Mixed as Investors Step Back Following Rally	12-21	MT
Japanese Shares Slip Back into Red as Wall Street Ends Winning Streak Ahead of Key US Data	12-21	MT
JCR Pharmaceuticals' Partner Takeda to Scrap Gene Therapy Collaboration	12-21	MT
JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Announces Discontinuation of Gene Therapy Collaboration	12-20	CI
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo	12-20	CI
JCR Pharmaceuticals' Metabolic Disease Drug Candidate Granted FDA's Orphan Drug Designation	12-15	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	12-13	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	12-12	CI
Japanese Shares Rebound on Wednesday, Boosted by Automotive Stocks	11-22	MT
JCR Pharmaceuticals' Fiscal H1 Attributable Profit Climbs on Increased Drug Sales	11-22	MT

Chart JCR Pharmaceuticals Co., Ltd.

Duration

Period

More charts

Company Profile

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment segment engages in the purchase and sale of the medical and research equipment.

Sector

Pharmaceuticals

Calendar

24/07/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for JCR Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

606 JPY

Average target price

851.4 JPY

Spread / Average Target

+40.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JCR PHARMACEUTICALS CO., LTD.	-48.29%	473M
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+47.26%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+18.40%	247B
ROCHE HOLDING AG	+3.64%	229B
NOVARTIS AG	+12.98%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B

Other Pharmaceuticals